RT Journal Article
SR Electronic
T1 Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.28.21268468
DO 10.1101/2021.12.28.21268468
A1 Vadrevu, Krishna Mohan
A1 Reddy, Siddharth
A1 Jogdand, Harsh
A1 Ganneru, Brunda
A1 Mirza, Nizam
A1 Tripathy, V.N.
A1 Singh, Chandramani
A1 Khalatkar, Vasant
A1 Prasanth, Siddaiah
A1 Rai, Sanjay
A1 Ella, Raches
A1 Blackwelder, William
A1 Prasad, Sai
A1 Ella, Krishna
YR 2021
UL http://medrxiv.org/content/early/2021/12/29/2021.12.28.21268468.abstract
AB Background We assessed the safety, reactogenicity, and immunogenicity of BBV152 in an open-label age de-escalation study in three age cohorts of children from 18 years of age down to 2 years of age.Methods This was a phase 2/3 open-label, multi-centre study done across six hospitals in India. All children received two 0.5mL doses of BBV152 (Covaxin®, Bharat Biotech International Ltd., Hyderabad, India), which is the same formulation indicated in adults. Participants were monitored for adverse events, and post-vaccination blood draws were collected to assess neutralising antibodies. A total of 526 children were enrolled into Group 1 (ages 12 through 18 years, n=176), Group 2 (ages 6 through 12 years, n=175), Group 3 (ages 2 through 6 years, n=175).Findings There were no serious adverse events, deaths, or withdrawals due to an adverse event during the study. Vaccination with BBV152 was generally well tolerated, with no substantial difference in reactogenicity profiles between the different age groups. Similar immune responses were measured as microneutralisation (MNT) antibody titers in all three age groups. Vaccine-induced MNT responses in all groups were comparable to BEI reference sera run in the same assay. Seroconversion (measured by Plaque Reduction Neutralization Test (PRNT)) achieved high levels (95-98%) in all three groups four weeks after the second vaccination. The PRNT GMT ratio was 1·76 (95%CI: 1.32 – 2.33) (GMT all children subgroup / GMT in adults) had a lower limit ≥ 1, indicating superior antibodies in children when compared to adults. Vaccine responses were skewed towards a Th1 response with IgG1/IgG4 ratios above 1.Interpretation BBV152 is well tolerated and immunogenic in children from 18 years down to 2 years of age. Immunogenicity analysis (by PRNT) shows superior antibody responses were observed in children compared to adults, suggesting that BBV152 will also be efficacious in this age group.Competing Interest StatementThis work was funded by Bharat Biotech International Limited. KMV, SR, BR and SP, are employees of Bharat Biotech, with no stock options or incentives. Co-author, KE, is the Chairman and Managing Director of Bharat Biotech and owns equity in the company. RE and WB are independent clinical development and statistical consultants, respectively. NM, VNT, CS, VK, SP, NP, SRa, were principal investigators representing the study sites.Clinical TrialRegistered with the Clinical Trials Registry (India) No. CTRI/2021/05/033752Funding StatementThe sponsor of the study had no role in data collection, data analysis, data interpretation, or writing the report. A contract research organisation (CRO) was responsible for data analysis and generating the report. The unblinded CRO and several authors from Bharat Biotech had full access to the data in the study. Authors from Bharat Biotech had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. Institutional Ethics Committee: ECR/1460/Inst/TG/2020 of Pranaam Hospital gave ethical approval for this work 2. Institutional Ethics Committee: ECR/1387/Inst/BR/2020 of All India Institute of Medical Sciences gave ethical approval for this work 3. Institutional Ethics Committee: ECR/134/Inst/KA/2013/RR-19 of Cheluvambha Hospital gave ethical approval for this work 4. Institutional Ethics Committee: ECR/608/Inst/MH/2014/RR-20 of Meditrina Institute of Medical Sciences gave ethical approval for this work. 5. Institutional Ethics Committee: ECR/1017/Inst/UP/2017/RR-21 of Prakhar Hospital gave ethical approval for this work. 6. Institutional Ethics Committee: ECR/538/Inst/DL/2014/RR-20 of All India Institute of Medical Sciences gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.